Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > MHLW Panel on Generic Industry Structure
MHLW Panel on Generic Industry Structure
-
MHLW Panel Draws Up Plans for Generic Industry Shakeup in Final Report
May 23, 2024
-
MHLW’s Generic Industry Panel to Call for 5-Year Intensive Reform Period
April 26, 2024
-
MHLW Generic Panel Outlines Plan to Drive Industry Revamp within Specific Time Frame
March 28, 2024
-
MHLW to Ask All Generic Makers in Japan to Execute Self-Inspections
March 4, 2024
-
Generic Firms Required to Disclose Supply Info from June after Pilot Rollout of Company Indicators
February 5, 2024
-
Health Ministry Panel Explores Vision for Generic Industry, Eyes Structural Reform in 5 Years
December 26, 2023
-
Authorized Generics Cannot be Regulated Now but Must Be Watched Closely: MHLW Panel Members
December 5, 2023
-
Generic Study Group Discusses Industry Shake-Up through Consortia
November 14, 2023
-
MHLW Panel Proposes Assessing Generic Makers’ Efforts toward Stable Supplies, Reflecting Results in Pricing
October 12, 2023
-
MHLW Proposes Curbing Entries of Generic Makers That Threaten Stable Supplies
September 20, 2023
-
MHLW Generics Study Group Discusses Yardsticks to Gauge Manufacturers’ Efforts towards Stabilizing Supplies
August 22, 2023
-
Generics Panel Initiates Debate toward Proposing Stable Supply Measures, Interim Report Slated for October
August 1, 2023
-
Panel on Generic Industry to Boot Up July 31, Report Expected by Fall
July 25, 2023
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…